Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 in Japanese Subjects With Lower-risk Myelodysplastic Syndromes
NCT03906695Phase 1Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in myelodysplastic syndrome (MDS) (5 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Mar 2019; status: active, not recruiting.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03906695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906695.